Search Results
Results found for "Aurelien Rizk"
- Dr. Aurélien Rizk | Dr. GPCR Ecosystem
Aurélien Rizk About Dr. Aurélien Rizk "Dr. Integrating Mathematical Models and Biology: A Fascinating Discussion Yamina and Aurelien Rizk had a GPCRs, Software, and Fluid Dynamics Yamina Berchiche and Aurelien Rizk discussed the complexities of Aurelien Rizk also contributed to the conversation, highlighting the complexity of the process. Rizk discussed the differences between academia and the biotech industry, with Aurelien Rizk sharing
- Dr. Yamina Berchiche | Dr. GPCR Ecosystem
Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev .
- 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks 📌 Limited spots—sign up before March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research | Dr. GPCR Ecosystem
metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks metabolism & clearance✅ PK-PD modeling & therapeutic profiles✅ Early safety assessments & toxicity risks
- Foundry for GPCR Organizations | Dr. GPCR Ecosystem
Expert support, trusted CROs, and ready-to-use tools to accelerate GPCR drug discovery, reduce risk, our nonprofit team for expert guidance, trusted CRO collaborations, and field-tested tools that de-risk De-risk decisions: gain expert strategic guidance on study design, timelines, and partner selection before Our core support areas: Discovery Consulting & Strategy Expert guidance to de-risk projects, refine strategy you are in your discovery journey, the Foundry helps GPCR biotech companies move faster and reduce risk
- Yamina's Corner | Dr. GPCR Ecosystem
Fuel Discovery VC Due Diligence & De-risking For Venture Capital Firms De-risk GPCR Investments: Identify Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic focused, scientific expertise that accelerates complex GPCR discovery programs, ensuring clarity and de-risking Foundation of Every Successful Partnership My advisory is built on principles that ensure clarity, minimize risk This ensures robust, defensible decisions that de-risk your program from early discovery to regulatory
- Session IV | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Mitochondrial Morphology in Axons Joseph Duman Bai1 Is A Novel Neuronal Substrate Of The Psychiatric Risk Baylor College of Medicine Kimberley Tolias Lab Bai1 Is A Novel Neuronal Substrate Of The Psychiatric Risk Tuberous Sclerosis Complex and then moved to the Francis Crick Institute working on the psychiatric risk
- Interrogating Multiscale Receptors Functions in Space
understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk
- Dr. Jean Martin Beaulieu | Dr. GPCR Ecosystem
understanding how cellular and molecular mechanisms regulated by psychoactive drugs intersect with genetic risk identified interactions between cellular mechanisms engaged by D2R and psychiatric drugs with genetic risk
- 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles ✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics ✅ PK-PD Modeling – Predicting drug behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery | Dr. GPCR Ecosystem
pharmacokinetics ✅ PK-PD Modeling – Predicting drug behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks pharmacokinetics✅ PK-PD Modeling – Predicting drug behavior, non-linear PK✅ Early Drug Safety – Toxicity risks
- pharmacology at your fingertips terrys corner launches | Dr. GPCR Ecosystem
GPCR Weekly: ♦️ Yamina’s Corner—GPCR consulting to de-risk and accelerate your pipeline ♦️ Celtarys’
- VC Insights | Dr. GPCR Ecosystem
nice to have” tests that stall timelines without payoff Match experiments to the specific phase and risk tolerance of the asset De-risk Your CRO Strategy I evaluate, select, and manage CROs that are fit-for-purpose—saving
- Celtarys Research | Dr. GPCR Ecosystem
biochemists Celtarys empowers medicinal biochemists by providing innovative fluorescent probes that de-risk www.ecosystem.drgpcr.com/celtarys-research Services & Expertise Fluorescent Probes Innovative fluorescent probes that de-risk
- Dr. Demet Araç | Dr. GPCR Ecosystem
Jose Rizo-Rey as a graduate student to elucidate the mechanisms of neurotransmitter release.
- GPCR Courses
Master strategic planning, risk assessment, and collaboration tools to boost efficiency and project success
- Session I | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Jose Rizo-Rey as a graduate student to elucidate the mechanisms of neurotransmitter release.
- Content Guidelines | Dr. GPCR Ecosystem
You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy
- Content and Conduct Policy | Dr. GPCR Ecosystem
You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy
- Fresh, Fresh, GPCR News ❇ Feb 17 - 23, 2025 | Dr. GPCR Ecosystem
Metabolism – Distribution, renal/hepatic pathways, and elimination 🔹 Safety First – Identifying toxicity risks
- Terms and Conditions | Dr. GPCR Ecosystem
DISCLAIMER OF WARRANTIES: CUSTOMER AGREES THAT HE/SHE/IT IS MAKING USE OF THE SERVICES AT HIS/SHE/ITS OWN RISK








